Compared to insulin therapy, 57 and 30 patients would need to be treated with a GLP-1RA over a mean of 2.3 years to prevent one case of all-cause mortality and hospitalized hypoglycemia, respectively. The gene discussed is INS; the disease is Hypoglycemia.